ClinicalTrials.gg
CompletedNCT03392961Updated Jan 23, 2018

Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD

A Phase 1 interventional study of IN-105 (Insulin Tregopil) and Placebo comparator in Type 2 Diabetes Mellitus, sponsored by Biocon Limited. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Biocon Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2014, 12 years 4 months ago, and no results have been posted to the registry.
  • Registered 3 years 8 months after the study started (first participant enrolled Mar 2014, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study to evaluate the PK and PD of oral IN-105 (Insulin Tregopil) w.r.t. time of dosing prior to meal, duration between meals and type of meal .

Read the detailed description

A Phase 1, Randomized, Placebo Controlled, Crossover Trial in Type 2 Diabetes Patients to evaluate the effect of pre-meal dosing time, inter-meal interval and meal composition on the PK and PD of IN-105 (Insulin Tregopil), an oral insulin; conducted in 3 sequential cohorts in an adaptive manner .

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Oral insulin
  • Dosing time
  • Insulin concentration
  • Prandial insulin
  • Post Prandial Glucose (PPG)
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 51 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Biocon Limited is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient should have an established diagnosis of T2DM per ADA 2013 criteria for at least 1 year prior to screening and are on metformin treatment for at least a month before screening.
  2. (BMI) of 18.5 to 40.00 kg/m2, both inclusive
  3. Glycosylated () ≤ 9.5%.
  4. Hemoglobin ≥9.0 g/dL.
  5. No abnormality in the at screening.
  6. Fasting plasma glucose levels less than 140 mg/dL at screening.
  7. The patient should be ready to give a written and signed before starting any protocol-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. History of to insulins or insulin analogues.
  2. Evidence of the following (either due to improper diabetes control or due to secondary complications following diabetes).

    1. History of ≥2 episodes of severe hypoglycemia within 6 months before screening or history of hypoglycemia unawareness as judged by the investigator.
    2. History of ≥1 episodes of hyperglycemic hyperosmolar state or emergency room visits for uncontrolled diabetes leading to hospitalization in the 6 months prior to screening.
    3. History of limb amputation as a complication of diabetes during his/her lifetime or any vascular procedure during the 1 year prior to screening.
    4. History of diabetic foot or diabetic ulcers in the past 1 year prior to screening.
    5. History of severe form of neuropathy or cardiac autonomic neuropathy (determined when obtaining patient history).
  3. Presence of any of the following:

    1. Serological evidence of (HIV), (HBsAg) or infection at screening.
    2. Any abnormality in the safety laboratory tests conducted at screening.
    3. Impaired hepatic function at screening [ (ALT) or aspartate aminotransferase (AST) value >2 times the upper limit of the reference range and/or serum 1.5 times the upper limit of the reference range] which investigator considers clinically significant.
    4. Evidence of clinically significant chronic renal disease (e.g. nephrotic syndrome, diabetic nephropathy) as assessed by the investigator at screening
  4. History or use of the following:

    1. Patients on OADs other than metformin for previous three months prior to screening.
    2. Patients who have received ≥14 consecutive days of oral, intravenous, or inhaled therapy within the past 1 year or have received steroids by any route within 4 weeks immediately preceding screening visit (intra-nasal, intra ocular, and topical steroid use is allowed).
  5. Receipt of another drug in the 4 weeks prior to screening, or within 5 half-lives of the another investigational drug at screening visit (whichever is longer), or scheduled for another investigational drug during the current study period.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    IN-105 (Insulin Tregopil)

    Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal. Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively. Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F).

    Drug: IN-105 (Insulin Tregopil)

  • Placebo comparator
    Placebo tablet

    Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal. Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively. Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F).

    Other: Placebo comparator

Interventions

  • 15 mg strength tablets for oral use used at a dose of 30 mg

  • OtherPlacebo comparator

    Placebo tablet for oral use

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 1)

    Area under the plasma concentration-time curve (AUC0-last; from dosing time to 180 minutes post meal, extrapolated) after single dose administration in the 30 ,20 and 10 minute pre-meal dosing groups

    Time frame: from dosing time to 180 minutes post meal, extrapolated

  2. The maximum observed plasma drug concentration (Cmax) will be assessed (Cohort 1)

    The maximum observed plasma drug concentration after single dose administration (Cmax)

    Time frame: from dosing time to 180 minutes post meal

  3. Glucose AUC0-t will be assessed (Cohort 1)

    Glucose AUC0-t \[AUC both above and below the baseline values\]

    Time frame: from dosing time to 180 minutes post meal

  4. Glucose concentration (Cmin) will be assessed (Cohort 1)

    Minimum observed glucose concentration (Cmin)

    Time frame: from dosing time to 180 minutes post meal

  5. Glucose concentration (Tmin) will be assessed (Cohort 1)

    Time of minimum observed glucose concentration (Tmin)

    Time frame: from dosing time to 180 minutes post meal

  6. Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 2)

    Area under the plasma concentration-time curve (AUC0-last; time of dosing to 180 minutes post dose, extrapolated) after single dose administration in morning and afternoon in the 4, 5 and 6 h inter-meal interval groups.

    Time frame: time of dosing to 180 minutes post dose,extrapolated

  7. The maximum observed plasma drug concentration (Cmax) will be assessed. (Cohort 2)

    The maximum observed plasma drug concentration after single dose administration (Cmax)

    Time frame: time of dosing to 180 minutes post dose

  8. Glucose AUC0-t will be assessed (Cohort 2)

    Glucose AUC0-t \[AUC both above and below the baseline values\]

    Time frame: time of dosing to 180 minutes post dose

  9. Glucose concentration (Cmin) will be assessed (Cohort 2)

    Minimum observed glucose concentration (Cmin)

    Time frame: time of dosing to 180 minutes post dose

  10. Glucose concentration (Tmin) will be assessed (Cohort 2)

    Time of minimum observed glucose concentration (Tmin)

    Time frame: time of dosing to 180 minutes post dose

  11. Area under the plasma concentration-time curve (AUC0-last) will be assessed (Cohort 3)

    Area under the plasma concentration-time curve (AUC0-last) for high-fat, high-fibre and ADA meal groups after single dose administration in morning and afternoon

    Time frame: time of dosing to 180 minutes post dose,extrapolated

  12. The maximum observed plasma drug concentration (Cmax) will be assessed (Cohort 3)

    The maximum observed plasma drug concentration after single dose administration (Cmax)

    Time frame: time of dosing to 180 minutes post dose

  13. Glucose AUC0-t will be assessed (Cohort 3)

    Glucose AUC0-t \[AUC both above and below the baseline values\]

    Time frame: time of dosing to 180 minutes post dose

  14. Glucose concentration (Cmin) will be assessed. (Cohort 3)

    Minimum observed glucose concentration (Cmin)

    Time frame: time of dosing to 180 minutes post dose

  15. Glucose concentration (Tmin) will be assessed. (Cohort 3)

    Time of minimum observed glucose concentration (Tmin)

    Time frame: time of dosing to 180 minutes post dose

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event including hypoglycemia that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Through study completion, approximately 3 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Khedkar A, Lebovitz H, Fleming A, Cherrington A, Jose V, Athalye SN, Vishweswaramurthy A. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus. Clin Pharmacol Drug Dev. 2020 Jan;9(1):74-86. doi: 10.1002/cpdd.730. Epub 2019 Aug 7. PubMed 31392840 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2014, 3 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Jan 8, 2018
StartActual
Mar 27, 2014
Primary completionActual
Jul 1, 2014
CompletionActual
Jul 1, 2014
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392961
Lead sponsor
Biocon Limited
Responsible party
Sponsor
First posted
Jan 8, 2018
Start date
Mar 27, 2014
Primary completion
Jul 1, 2014
Completion
Jul 1, 2014
Last update
Jan 23, 2018

Study contacts

Juan Carlos Rondon, M.D,JD
principal investigator · Elite Research Institute, 15705 NW 13th Avenue, Miami, Florida 33169

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin tregopil

Start the discussion